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Abstract (150 words)
Acute respiratory infections, including pneumonia and influenza, are the S t" leading cause of United
States and worldwide deaths. Newly emerging pathogens signaled the need for an advanced generation of
vaccine technology.. Human bronchial-tracheal epithelial tissue was bioengineered to detect, identify,
host and study the pathogenesis of acute respiratory viral disease. The 3-dimensional (3D) human lung
epithelio-mesechymal tissue-like assemblies (HLEM TLAs) share characteristics with human respiratory
epithelium: tight junctions, desmosomes, microvilli, functional markers villin, keratins and production of
tissue mucin. Respiratory Syntial Virus (RSV) studies demonstrate viral growth kinetics and membrane
bound glycoproteins up to day 20 post infection in the human lung-orgainoid infected cell system. Peak
replication of RSV occurred on day 10 at 7 log 10 particles forming units per ml/day. HLEM is an
advanced virus vaccine model and biosentinel system for emergent viral infectious diseases to support
DoD global surveillance and military readiness.
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Objectives (<30 words)
1. Describe advanced bioengineered model for viral respiratory disease
2. Explain the relevance of using a regenerative, bioengineered human lung model for viral vaccine
production
Intended Audience
Researchers, epidemiologists, and preventive medicine physicians
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